Form 4: Tevogen Bio Holdings Inc. Director Receives Stock Grant

Victor J. Sordillo, a Director at Tevogen Bio Holdings Inc., was granted 40,000 shares of common stock under the company's 2024 Omnibus Incentive Plan.

Summary

• Victor J. Sordillo, a Director of Tevogen Bio Holdings Inc., received a grant of 40,000 shares of common stock on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The shares vest in three equal installments based on specific revenue milestones and continued service.
• Vesting conditions include achieving aggregate revenues of $50 million, $100 million, and $150 million since the grant date, on the first, second, and third anniversaries of the grant date, respectively.
• The reporting person must remain in service with the Issuer on each applicable vesting date for the shares to vest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns director compensation with company performance through revenue-based vesting, but the achievement of these targets remains a key uncertainty.

Positives

• Director Sordillo received a significant stock grant, indicating potential alignment of management interests with shareholder value.
• The vesting structure is tied to revenue milestones, incentivizing growth and performance for the company.

Negatives

• The vesting of the shares is contingent on future revenue achievements, which are not guaranteed.
• The grant is subject to the reporting person remaining in service, introducing potential attrition risk.

Risks

• Failure to achieve the specified revenue targets ($50M, $100M, $150M) by the respective anniversaries will result in forfeiture of unvested shares.
• The reporting person's departure from the company before a vesting date will lead to the forfeiture of shares scheduled to vest on that date.
• The value of the stock grant is subject to market fluctuations and the overall performance of Tevogen Bio Holdings Inc.

Future Outlook

The future outlook for the stock grant is dependent on the company achieving significant revenue growth targets and the continued service of the reporting person.

Industry Context

StockSavvy.ai notes that equity grants tied to performance metrics like revenue are a common practice in the biotechnology sector to align executive incentives with long-term value creation and de-risk compensation.

Stakeholder Impact

• Shareholders: The grant incentivizes a director to focus on revenue growth, potentially leading to increased shareholder value if targets are met. However, dilution could occur if the stock price is low at vesting.
• Employees: The success tied to revenue targets may indirectly benefit employees through company growth and potential future incentives.
• Management: Aligns the interests of the director with the company's financial performance.

Next Steps

• Monitor Tevogen Bio Holdings Inc.'s revenue growth to assess progress towards vesting milestones.
• Observe the continued service of Victor J. Sordillo with the company.

Key Dates

Keywords

Tevogen Bio Holdings Inc., Victor J. Sordillo, Form 4, Stock Grant, Restricted Stock, Omnibus Incentive Plan, Vesting Schedule, Revenue Milestones, Director Compensation